Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 2/20 | 0.46 |
| ▸ | ABL1 | P00519 | 2/20 | 0.46 |
| ▸ | EGFR | P00533 | 2/20 | 0.46 |
| ▸ | HCK | P08631 | 2/20 | 0.46 |
| ▸ | SRC | P12931 | 2/20 | 0.46 |
| ▸ | KDR | P35968 | 2/20 | 0.46 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.46 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.46 |
| ▸ | MTOR | P42345 | 2/20 | 0.46 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.46 |
| ▸ | EPHB4 | P54760 | 2/20 | 0.46 |
| ▸ | PRKDC | P78527 | 2/20 | 0.46 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.46 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.45 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.45 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.45 |
| ▸ | BUB1 | O43683 | 1/20 | 0.39 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.38 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.38 |
| ▸ | HTR6 | P50406 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18788892 | 0.88 | GABRG2 (0.43) | PIK3CDABL1EGFRHCKSRC | |
| SCHEMBL3269495 | 0.84 | PIK3CD (0.47) | PIK3CDABL1EGFRHCKSRC | |
| SCHEMBL1273077 | 0.84 | HTR6 (0.49) | PIK3CDABL1EGFRHCKSRC | |
| SCHEMBL819797 | 0.82 | PIK3CD (0.46) | PIK3CDABL1EGFRHCKSRC | |
| SCHEMBL29829168 | 0.82 | OXER1 (0.50) | PIK3CDABL1EGFRHCKSRC | |
| SCHEMBL18805035 | 0.82 | PIK3CD (0.46) | PIK3CDABL1EGFRHCKSRC | |
| SCHEMBL265019 | 0.82 | PIK3CA (0.46) | PIK3CDABL1EGFRHCKSRC | |
| SCHEMBL312329 | 0.82 | PIK3CD (0.51) | PIK3CDABL1EGFRHCKSRC | |
| Methane SCHEMBL6390810 | 0.82 | HTR6 (0.48) | PIK3CDABL1EGFRHCKSRC | |
| SCHEMBL2006239 | 0.82 | OXER1 (0.50) | PIK3CDABL1EGFRHCKSRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115057803-A | S- (methyl-d) 3 ) Synthetic method and application of phenylether substances | 杭州师范大学 | 2022-09-16 | — | — | CN | claimed |
| EP-4140974-B1 | METHODS OF IRON CATALYZED C-H BOND AMINATION | VERSITECH LTD (CN) | 2025-05-14 | — | — | EP | disclosed |
| US-12208088-B2 | Spirocyclic 2,3-dihydro-7-azaindole compounds and uses thereof | GENENTECH, INC. (US) | 2025-01-28 | — | — | US | disclosed |
| US-12098126-B2 | Methods of iron catalyzed C-H bond amination | VERSITECH LIMITED (CN) | 2024-09-24 | — | — | US | disclosed |
| CN-115057803-B | S- (methyl-d) 3 ) Synthesis method and application of phenyl sulfide substance | 杭州师范大学 | 2023-11-24 | — | — | CN | disclosed |
| US-20230121302-A1 | METHODS OF IRON CATALYZED C-H BOND AMINATION | VERSITECH LIMITED (CN) | 2023-04-20 | — | — | US | disclosed |
| EP-4166531-A1 | PROCESS FOR PREPARING A PHENOLIC HYDROCARBON | Studiengesellschaft Kohle mbH (DE) | 2023-04-19 | — | — | EP | disclosed |
| EP-4140974-A1 | METHODS OF IRON CATALYZED C-H BOND AMINATION | The University of Hong Kong (HK) | 2023-03-01 | — | — | EP | disclosed |
| CN-115710210-A | Iron catalyzed amination of C-H bonds | 港大科桥有限公司 | 2023-02-24 | — | — | CN | disclosed |
| US-20220370420-A1 | SPIROCYCLIC 2,3-DIHYDRO-7-AZAINDOLE COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2022-11-24 | — | — | US | disclosed |
| EP-2108642-A1 | JAK INHIBITOR | Kyowa Hakko Kirin Co., Ltd. (JP) | 2009-10-14 | — | — | EP | disclosed |
| US-20090054407-A1 | Nitrogen-containing heterocyclic compound | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2009-02-26 | — | — | US | disclosed |
| CN-101163675-A | Nitrogen-containing heterocyclic compound | KYOWA HAKKO KOGYO KK (JP) | 2008-04-16 | — | — | CN | disclosed |
| EP-1880993-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2008-01-23 | — | — | EP | disclosed |
| US-20070232627-A1 | ANTI-VIRAL COMPOUNDS | ABBVIE INC. | 2007-10-04 | — | — | US | disclosed |
| US-7129250-B2 | Neuroprotective and anti-proliferative compounds | AEGERA THERAPEUTICS INC. (CA) | 2006-10-31 | — | — | US | disclosed |
| US-20040220202-A1 | Neuroprotective and anti-proliferative compounds | AEGERA THERAPEUTICS INC. (CA) | 2004-11-04 | — | — | US | disclosed |
| US-20040102467-A1 | Neuroprotective and anti-proliferative compounds | AEGERA THERAPEUTICS INC. (CA) | 2004-05-27 | — | — | US | disclosed |
| EP-1283836-A2 | NEUROPROTECTIVE AND ANTI-PROLIFERATIVE COMPOUNDS | Aegera Therapeutics Inc. (CA) | 2003-02-19 | — | — | EP | disclosed |
| WO-2001087887-A2 | NEUROPROTECTIVE AND ANTI-PROLIFERATIVE COMPOUNDS | AEGERA THERAPEUTICS INC. (CA) | 2001-11-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12208088-B2 | Spirocyclic 2,3-dihydro-7-azaindole compounds and uses thereof | HIPK1, NEK1, HIPK2 | PIK3CD 1332/4885ABL1 1309/4885EGFR 4781/4885 |
| US-20220370420-A1 | SPIROCYCLIC 2,3-DIHYDRO-7-AZAINDOLE COMPOUNDS AND USES THEREOF | HIPK1, NEK1, HIPK2 | PIK3CD 1332/4885ABL1 1309/4885EGFR 4781/4885 |
| US-20040220202-A1 | Neuroprotective and anti-proliferative compounds | NLN, MKI67, BDNF | PIK3CD 1902/4885ABL1 4106/4885EGFR 2719/4885 |
| US-20090054407-A1 | Nitrogen-containing heterocyclic compound | NR4A1, NR5A2, PRMT8 | PIK3CD 4159/4885ABL1 325/4885EGFR 1790/4885 |
| US-12098126-B2 | Methods of iron catalyzed C-H bond amination | FTH1, FECH, HCCS | PIK3CD 4465/4885ABL1 343/4885EGFR 3449/4885 |
| US-20230121302-A1 | METHODS OF IRON CATALYZED C-H BOND AMINATION | FTH1, FECH, HCCS | PIK3CD 4465/4885ABL1 343/4885EGFR 3449/4885 |
| US-20070232627-A1 | ANTI-VIRAL COMPOUNDS | HAVCR2, MAVS, EIF2AK2 | PIK3CD 2670/4885ABL1 92/4885EGFR 2701/4885 |
| US-20040102467-A1 | Neuroprotective and anti-proliferative compounds | MKI67, NLN, BDNF | PIK3CD 1834/4885ABL1 4007/4885EGFR 2740/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.